Replies to post #731443 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Excellent DD, DD. Beginning to end. Thank you.

Some reflections.

Those fast upcoming multiple combination trials LP discussed at the ASM, might very well be initiated in the UK utilizing the newly created MHRA phase i, ii, and iii trial templates for standardized studies. Where, in those cases, tumor shrinkage/response will accelerate the process for various cancer indication trials. I also believe the EDEN automated system utilized in facilities and point of care will additionally standardize those trial (and commercial) processes. These appear to be major components of a master plan.

Until recently, standardization systems (e.g. trial templates, automated closed system manufacturing) has been the once quiet giant infrastructure being cooperatively developed by industry, regulators, institutions/hospitals and other collaborators. Quiet no longer. And yes, sorry not sorry to bears, it would seem DCVax’s platform is an integral initial subject used to run the gauntlet for this new UK structure. Lest we forget MHRA’s recent comment that in the future she, Dr. June Raine, (retiring) CEO MHRA) could see platform approvals as opposed to solely product approvals. JMHO.

[learningcurve2020]

I'm sure he benefits Advent.  

[learningcurve2020]

Inmune looks to be in dire financial shape too. 


>>Despite the challenging financial performance, the company raised substantial capital through several stock offerings, resulting in an increase in additional paid-in capital. Looking ahead, Inmune Bio faces substantial liquidity challenges, with management exploring various financing strategies to support ongoing operations and mitigate the going concern risk.

https://www.tipranks.com/news/company-announcements/inmune-bio-reports-increased-losses-amid-financing-efforts

[Truthfan]

“Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. He was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA including Achilles Therapeutics Ltd, Autolomous Ltd, Autolus Ltd, NWBio Therapeutics and INmuneBio Inc, which he helped take through Nasdaq listing and for which he acts as CSO.”

A point of interest: Kwok Pang, co-founder of Autolomous along with Lowdell, is now Chief Digital Officer at UK’s Adthera Bio…..perhaps another connecting dot to watch as the biotech industry moves further into restructuring and process efficiency through digitalization.
https://www.adthera.bio/

[Doc logic]

The Danish Dude,

Now you know why up to 30 hours spent on product release for a single batch of L by a Qulaified Person like Dr. Mark Lowdell, one of only two academics in this position according to the article cited, has been such a difficult work around. Digitized oversight that has been developed and Flaskworks change all of this; ). Notice his expertise with NK cells. NWBO has never been doing this “alone”. Best wishes.